Genomics-Guided Management of Recurrent and Metastatic Female Adnexal Tumors of Probable Wolffian Origin: A Case Report and Review of Therapeutic Strategies
Case Reports in Oncology · 2026-08-24 · 19 (1) · 1437-1450
DOI: 10.1159/cro/abzag031 ↗Abstract
Introduction: Female adnexal tumors of probable Wolffian origin (FATWO) are exceptionally rare neoplasms arising from mesonephric remnants. While usually considered to have a benign course, a subset demonstrates recurrent or metastatic potential, and no standardized treatment recommendations exist. Case Presentation: We report the case of a woman in her early sixties with a primary ovarian FATWO, initially treated by complete surgical resection. Despite this, she developed multiple recurrences and ultimately metastatic disease. The patient underwent repeated cytoreductive surgeries and received systemic therapies including carboplatin/paclitaxel, bevacizumab maintenance, and pegylated liposomal doxorubicin. Given the lack of established treatment options, comprehensive multi-omics profiling was performed within the Molecularly Aided Stratification for Tumor Eradication (MASTER) program, including extensive genomic analyses. Molecular characterization identified an alteration affecting the mitogen-activated protein kinase (MAPK) signaling pathway. The findings were discussed in a multidisciplinary molecular tumor board, which recommended targeted therapy with a mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor based on the detected pathway alteration. Following reimbursement approval, treatment with binimetinib was initiated. However, at the time of therapy initiation, the patient’s clinical condition had markedly deteriorated due to progressive tumor burden. She was admitted to palliative care shortly thereafter and passed away under supportive measures. Conclusion: This case illustrates the clinical challenges associated with recurrent and metastatic FATWO and underscores the potential value of comprehensive molecular profiling in rare gynecologic tumors lacking standardized treatment strategies. To our knowledge, this represents the first reported case of recurrent FATWO undergoing extensive multi-omics analysis within a structured precision oncology program with subsequent molecular tumor board-guided therapeutic recommendation.
EUVIMED